You are not currently logged in.
Access JSTOR through your library or other institution:
Cost‐Effectiveness Analysis of a Silver‐Coated Endotracheal Tube to Reduce the Incidence of Ventilator‐Associated Pneumonia
Andrew F. Shorr , MD, MPH, Marya D. Zilberberg , MD, MPH and Marin Kollef , MD
Infection Control and Hospital Epidemiology
Vol. 30, No. 8 (August 2009), pp. 759-763
Published by: Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Stable URL: http://www.jstor.org/stable/10.1086/599005
Page Count: 5
You can always find the topics here!Topics: Intratracheal intubation, Hospital costs, Cost estimates, Savings, Cost savings, Cost estimation models, Sensitivity analysis, Health outcomes, Disease risk, Acquisition costs
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Objective. To conduct a cost‐effectiveness analysis of the economic outcomes of ventilator‐associated pneumonia (VAP) prevention associated with silver‐coated endotracheal tubes versus uncoated endotracheal tubes. Design. We used a simple decision model based on a hypothetical 1,000‐patient cohort intubated with silver‐coated or uncoated endotracheal tubes. The primary end point was marginal hospital savings per case of VAP prevented (savings from using silver‐coated endotracheal tubes minus acquisition cost divided by number of VAP cases prevented). Methods. We followed each branch of the decision model to VAP or no VAP and conducted Monte Carlo simulations and sensitivity analyses. Inputs for VAP incidence, relative risk reduction, and hospital costs were derived from publicly available sources. Relative risk reduction was derived from the pivotal study of the silver‐coated endotracheal tube. Results. In the base‐case analysis, we reduced the pivotal study relative risk in incidence of microbiologically confirmed VAP in patients intubated ⩾24 hours from 35.9% to 24%. Thus, 23 of 97 expected cases of VAP could be prevented with silver‐coated endotracheal tubes. The savings per case of VAP prevented was $12,840 in the base case, with assumed marginal VAP cost of $16,620 and costs of $90.00 for coated and $2.00 for uncoated endotracheal tubes. Estimates were most sensitive to assumptions regarding VAP cost and relative risk reduction with silver‐coated endotracheal tubes. Nonetheless, in multivariate sensitivity analyses, the silver‐coated endotracheal tubes yielded persistent savings (95% confidence interval, $9,630–$16,356) per case of VAP prevented. With other base‐case inputs held constant, break‐even cost for silver‐coated endotracheal tubes was $388. Conclusions. The silver‐coated endotracheal tube represents a strategy for preventing VAP that may yield hospital savings.
© 2009 by The Society for Healthcare Epidemiology of America. All rights reserved.